Oversold Conditions For Protalix BioTherapeutics (PLX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Friday, shares of Protalix BioTherapeutics Inc ( PLX) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $5.09 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 63.4. A bullish investor could look at PLX's 29.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of PLX shares:

Find out what 9 other oversold stocks you need to know about »

Protalix BioTherapeutics Inc 1 Year Performance Chart

Looking at the chart above, PLX's low point in its 52 week range is $4.71 per share, with $6.80 as the 52 week high point — that compares with a last trade of $5.09.


If you liked this article you might like

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

5 Stocks Under $10 Set to Soar

5 Stocks Insiders Love Right Now

5 Stocks Ready to Break Out and Soar Higher